サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1777378

心臓病学と神経学におけるIVDの世界市場

IVD in Cardiology and Neurology

出版日
ページ情報
英文 378 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
心臓病学と神経学におけるIVDの世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 378 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

心臓病学と神経学におけるIVDの世界市場は2030年までに278億米ドルに達する見込み

2024年に173億米ドルと推定される心臓病学と神経学におけるIVDの世界市場は、2024年から2030年にかけてCAGR 8.2%で成長し、2030年には278億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである器具は、CAGR 9.8%を記録し、分析期間終了までに170億米ドルに達すると予測されます。試薬・消耗品セグメントの成長率は、分析期間中CAGR 5.8％と推定されます。

米国市場は推定47億米ドル、中国はCAGR13.1％で成長予測

米国の心臓病学と神経学におけるIVD市場は、2024年に47億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに61億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.0％と8.0％と予測されています。欧州では、ドイツがCAGR 5.5%で成長すると予測されています。

心臓病学と神経学におけるIVD市場- 主要動向と促進要因のまとめ

心臓病学および神経学における体外診断（IVD）は急速に進化しており、疾患の早期発見、リスク評価、個別化治療戦略を可能にしています。心血管疾患と神経疾患は世界的に死亡率と身体障害の主要な原因となっているため、IVD技術は患者の予後改善に重要な役割を果たしています。バイオマーカーに基づく検査、分子診断、ポイントオブケア（POC）検査、デジタルヘルス統合の進歩がこの分野の技術革新を促進しています。

心臓病、脳卒中、神経変性疾患、認知障害の有病率の上昇に伴い、ヘルスケアプロバイダーや研究者は、正確な診断、疾患モニタリング、治療最適化のためにIVDソリューションへの依存度を高めています。高感度心臓・神経バイオマーカー、AI主導型診断、迅速検査ソリューションへの需要が市場成長を後押しし、臨床的意思決定を変革しています。

技術の進歩は心臓病学の体外診断用医薬品をどのように強化しているか？

心臓の体外診断の分野では、特に高感度アッセイ、ポイントオブケア心臓バイオマーカー検査、分子診断において画期的な進歩が見られます。最も重要な技術革新の一つは、心筋梗塞（MI）や急性冠症候群（ACS）の早期発見を可能にする高感度心筋トロポニン（hs-cTn）検査の開発です。これらの超高感度アッセイは、心筋トロポニン値の微細な変化を検出し、早期介入、リスク層別化の改善、入院の減少を可能にします。

もう一つの大きな進歩は、心血管疾患リスク評価のためのマルチバイオマーカー・パネルの統合です。従来は、脂質プロファイル（LDL、HDL、総コレステロール、トリグリセリド）が心血管の健康状態を評価する標準でした。しかし、最新のIVDソリューションは、包括的な心血管リスクの洞察を提供するために、高感度CRP（hs-CRP）、ナトリウム利尿ペプチド（BNP/NT-proBNP）、ミエロペルオキシダーゼ（MPO）などのバイオマーカーを組み込んでいます。これらの高度なバイオマーカー測定は、個別化された予防戦略や早期の心血管疾患（CVD）介入を可能にしています。

心臓マーカーのポイントオブケア（POC）検査の拡大も重要な動向です。ポータブル、迅速、ハンドヘルドのPOC分析装置により、現在では救急室、救急車、プライマリ・ケアの現場でリアルタイムでのトロポニン、Dダイマー、BNP検査が可能となっています。これにより、早期のトリアージ判断が大幅に改善され、所要時間が短縮され、病院前の心臓イベント管理が強化されました。さらに、ウェアラブル・バイオセンサーや遠隔心臓モニタリング機器の台頭により、継続的な心臓の健康状態の追跡が可能になり、積極的な介入や心不全や不整脈による入院の減少につながっています。

さらに、遺伝性心血管系疾患に対する分子・遺伝子検査は、疾患の予防と管理に変革をもたらしつつあります。家族性高コレステロール血症（FH）、肥大型心筋症（HCM）、QT延長症候群（LQTS）といった疾患の遺伝子スクリーニングがより利用しやすくなり、リスクのある個人の早期特定や、生活習慣や薬理学的介入を目標とすることができるようになっています。AIによるECG解釈とデジタル病理学の統合も、CVDの自動診断と予後予測を進めています。

神経分野のIVDを牽引する市場動向とは？

神経診断分野は、神経変性疾患、脳卒中、認知障害の負担増に後押しされ、急速な変貌を遂げています。最も重要な動向の一つは、アルツハイマー病（AD）とパーキンソン病（PD）に対する血液ベースのバイオマーカーの開発です。従来、アルツハイマー病の診断は脳脊髄液（CSF）分析またはPET画像診断に依存していたが、いずれも侵襲的で高価です。しかし、近年、βアミロイド（Aβ42/Aβ40比）、タウ蛋白（pTau-181、pTau-217）、ニューロフィラメント軽鎖（NfL）に対する血漿ベースのアッセイが進歩し、アルツハイマー病や他の神経変性疾患に対する非侵襲的でスケーラブルなスクリーニングが可能になりました。

もう一つの大きな動向は、神経学における分子診断、特に神経発達障害、てんかん、神経筋疾患の遺伝子検査の拡大です。次世代シーケンサー（NGS）やCRISPRを用いた診断法の進歩により、筋萎縮性側索硬化症（ALS）、多発性硬化症（MS）、遺伝性失調症などの疾患に関連する遺伝子変異の早期発見が可能となっています。このような精密診断ツールは、個別化治療の選択、早期介入、標的遺伝子治療を促進します。

脳卒中の診断と管理のためのIVDソリューションの台頭も市場成長の原動力となっています。従来、脳卒中診断は神経画像（CT、MRI）に依存していたが、グリア線維性酸性タンパク質（GFAP）、S100B、Dダイマーなどの脳卒中バイオマーカー・パネルの導入により、脳卒中の早期発見と虚血性脳卒中と出血性脳卒中の鑑別が強化されつつあります。POC血液ベースの脳卒中検査は、病院前の脳卒中評価のゲームチェンジャーとして台頭しており、迅速な介入と患者の転帰改善を可能にしています。

さらに、AIを活用した神経診断、デジタルバイオマーカー、遠隔モニタリングの統合が進んでおり、神経疾患の検出と進行追跡に変革をもたらしています。脳波、MRI、音声パターンのAIを活用した分析により、てんかん、認知症、運動障害の診断が改善されつつあり、ウェアラブル神経技術により、パーキンソン病、MS、脳卒中後のリハビリテーションのためのリアルタイムの神経モニタリングが可能となっています。

心臓病学と神経学におけるIVDの成長の原動力は？

循環器領域と神経領域のIVD市場は、心血管疾患や神経変性疾患の有病率の上昇、バイオマーカー探索の進歩、非侵襲的診断への需要の高まりなど、いくつかの主要な成長促進要因によって拡大しています。最も重要な成長要因のひとつは、CVDと脳卒中による世界の負担であり、これらは依然として世界の死因の上位を占めています。ヘルスケアシステムが早期発見、予防、個別化治療アプローチに注力する中、高感度心臓バイオマーカーと迅速脳卒中診断薬への需要が加速しています。

また、アルツハイマー病やパーキンソン病などの神経変性疾患の罹患率増加の一因となっている人口の高齢化も重要な推進力となっています。早期の発見と介入が優先される中、血液ベースのバイオマーカー、遺伝子スクリーニング、AIを活用した神経画像解析に基づくIVDソリューションが支持を集めています。

また、ポイントオブケア（POC）検査や分散型診断の採用が増加していることも、市場の成長を後押ししています。病院ベースの検査室検査からポータブルで迅速な診断ソリューションへのシフトは、迅速な意思決定、患者トリアージの改善、急性心疾患や神経疾患のより良い管理を可能にしています。救急医療、プライマリ・ケア、在宅診断の拡大に伴い、IVDメーカーはコンパクトで使いやすく、高感度のPOC検査プラットフォームに投資しています。

IVD主導の精密医療に対する規制と償還の支援も市場成長に影響を与える主要因です。政府やヘルスケア機関は、患者の転帰を最適化し医療費を削減するために、バイオマーカー主導の治療戦略、遺伝性疾患の遺伝子検査、AI統合診断を推進しています。さらに、デジタルヘルス技術や遠隔患者モニタリングへの投資の高まりが、AIを活用した心臓・神経診断の技術革新を促進しています。

セグメント

製品タイプ（装置、試薬・消耗品、ソフトウェア・サービス）、技術（免疫測定、分子診断、血液学、その他）、エンドユーザー（病院、臨床検査室、その他）

調査対象企業の例

  • Abbott Laboratories
  • Agilent Technologies
  • AliveCor
  • Becton, Dickinson and Company（BD）
  • bioMerieux S.A.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Hologic Inc.
  • LivaNova
  • Medtronic
  • Mindray Medical International Limited
  • Ortho Clinical Diagnostics
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP31707

Global IVD in Cardiology and Neurology Market to Reach US$27.8 Billion by 2030

The global market for IVD in Cardiology and Neurology estimated at US$17.3 Billion in the year 2024, is expected to reach US$27.8 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$17.0 Billion by the end of the analysis period. Growth in the Reagents & Consumables segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.7 Billion While China is Forecast to Grow at 13.1% CAGR

The IVD in Cardiology and Neurology market in the U.S. is estimated at US$4.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.1 Billion by the year 2030 trailing a CAGR of 13.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

IVD in Cardiology and Neurology Market - Key Trends & Drivers Summarized

In-vitro diagnostics (IVD) in cardiology and neurology is rapidly evolving, enabling early disease detection, risk assessment, and personalized treatment strategies. As cardiovascular and neurological disorders continue to be leading causes of mortality and disability worldwide, IVD technologies are playing a crucial role in improving patient outcomes. Advances in biomarker-based testing, molecular diagnostics, point-of-care (POC) testing, and digital health integration are driving innovation in this sector.

With the rising prevalence of heart disease, stroke, neurodegenerative disorders, and cognitive impairments, healthcare providers and researchers are increasingly relying on IVD solutions for accurate diagnosis, disease monitoring, and therapy optimization. The demand for high-sensitivity cardiac and neurological biomarkers, AI-driven diagnostics, and rapid testing solutions is fueling market growth and transforming clinical decision-making.

How Are Technological Advancements Enhancing IVD in Cardiology?

The field of cardiac in-vitro diagnostics has witnessed groundbreaking advancements, particularly in high-sensitivity assays, point-of-care cardiac biomarker testing, and molecular diagnostics. One of the most significant innovations is the development of high-sensitivity cardiac troponin (hs-cTn) tests, which enable the early detection of myocardial infarction (MI) and acute coronary syndrome (ACS). These ultrasensitive assays detect minute changes in cardiac troponin levels, allowing for earlier intervention, improved risk stratification, and reduced hospital admissions.

Another major breakthrough is the integration of multi-biomarker panels for cardiovascular disease risk assessment. Traditionally, lipid profiles (LDL, HDL, total cholesterol, and triglycerides) were the standard for evaluating cardiovascular health. However, modern IVD solutions now incorporate additional biomarkers such as high-sensitivity C-reactive protein (hs-CRP), natriuretic peptides (BNP/NT-proBNP), and myeloperoxidase (MPO) to provide comprehensive cardiovascular risk insights. These advanced biomarker assays are enabling personalized preventive strategies and early-stage cardiovascular disease (CVD) intervention.

The expansion of point-of-care (POC) testing for cardiac markers is another critical trend. Portable, rapid, and handheld POC analyzers now allow for real-time troponin, D-dimer, and BNP testing in emergency rooms, ambulances, and primary care settings. This has significantly improved early triage decisions, reduced turnaround times, and enhanced pre-hospital cardiac event management. Additionally, the rise of wearable biosensors and remote cardiac monitoring devices is enabling continuous cardiac health tracking, leading to proactive interventions and reduced hospitalizations for heart failure and arrhythmias.

Furthermore, molecular and genetic testing for inherited cardiovascular conditions is transforming disease prevention and management. Genetic screening for conditions such as familial hypercholesterolemia (FH), hypertrophic cardiomyopathy (HCM), and long QT syndrome (LQTS) is becoming more accessible, allowing early identification of at-risk individuals and targeted lifestyle or pharmacological interventions. The integration of AI-driven ECG interpretation and digital pathology is also advancing automated CVD diagnosis and prognosis prediction.

What Market Trends Are Driving IVD in Neurology?

The field of neurological diagnostics is undergoing rapid transformation, fueled by the increasing burden of neurodegenerative diseases, stroke, and cognitive disorders. One of the most significant trends is the development of blood-based biomarkers for Alzheimer’s disease (AD) and Parkinson’s disease (PD). Traditionally, the diagnosis of Alzheimer’s relied on cerebrospinal fluid (CSF) analysis or PET imaging, both of which are invasive and expensive. However, recent advancements in plasma-based assays for beta-amyloid (Aβ42/Aβ40 ratio), tau proteins (pTau-181, pTau-217), and neurofilament light chain (NfL) have enabled non-invasive and scalable screening for Alzheimer’s and other neurodegenerative diseases.

Another major trend is the expansion of molecular diagnostics in neurology, particularly in genetic testing for neurodevelopmental disorders, epilepsy, and neuromuscular conditions. Advances in next-generation sequencing (NGS) and CRISPR-based diagnostics are enabling early detection of genetic mutations linked to conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and hereditary ataxias. These precision diagnostic tools are facilitating personalized treatment selection, early interventions, and targeted gene therapies.

The rise of IVD solutions for stroke diagnosis and management is also driving market growth. Traditionally, stroke diagnosis relied on neuroimaging (CT, MRI); however, the introduction of stroke biomarker panels, including glial fibrillary acidic protein (GFAP), S100B, and D-dimer, is enhancing early stroke detection and differentiation between ischemic and hemorrhagic strokes. POC blood-based stroke tests are emerging as a game-changer for pre-hospital stroke assessment, allowing for rapid intervention and better patient outcomes.

Additionally, the growing integration of AI-driven neurodiagnostics, digital biomarkers, and remote monitoring is transforming neurological disease detection and progression tracking. AI-powered analysis of EEG, MRI, and speech patterns is improving the diagnosis of epilepsy, dementia, and movement disorders, while wearable neurotechnology is enabling real-time neuromonitoring for Parkinson’s, MS, and post-stroke rehabilitation.

What Is Driving the Growth of IVD in Cardiology and Neurology?

The IVD market in cardiology and neurology is expanding due to several key growth drivers, including the rising prevalence of cardiovascular and neurodegenerative diseases, advancements in biomarker discovery, and the growing demand for non-invasive diagnostics. One of the most significant growth drivers is the global burden of CVD and stroke, which remain the leading causes of death worldwide. As healthcare systems focus on early detection, prevention, and personalized treatment approaches, the demand for high-sensitivity cardiac biomarkers and rapid stroke diagnostics is accelerating.

Another critical driver is the aging population, which is contributing to the increased incidence of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. With early-stage detection and intervention becoming a priority, IVD solutions based on blood-based biomarkers, genetic screening, and AI-driven neuroimaging analysis are gaining traction.

The increasing adoption of point-of-care (POC) testing and decentralized diagnostics is also fueling market growth. The shift from hospital-based laboratory testing to portable, rapid diagnostic solutions is enabling quicker decision-making, improved patient triage, and better management of acute cardiac and neurological conditions. As emergency medicine, primary care, and home-based diagnostics expand, IVD manufacturers are investing in compact, user-friendly, and highly sensitive POC testing platforms.

Regulatory and reimbursement support for IVD-driven precision medicine is another major factor influencing market growth. Governments and healthcare agencies are promoting biomarker-driven treatment strategies, genetic testing for hereditary conditions, and AI-integrated diagnostics to optimize patient outcomes and reduce healthcare costs. Additionally, the rising investments in digital health technologies and remote patient monitoring are driving innovation in AI-powered cardiac and neurological diagnostics.

SCOPE OF STUDY:

The report analyzes the IVD in Cardiology and Neurology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Instruments, Reagents & Consumables, Software & Services); Technology (Immunoassays, Molecular Diagnostics, Hematology, Others); End-Use (Hospitals, Clinical Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Agilent Technologies
  • AliveCor
  • Becton, Dickinson and Company (BD)
  • bioMerieux S.A.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Hologic Inc.
  • LivaNova
  • Medtronic
  • Mindray Medical International Limited
  • Ortho Clinical Diagnostics
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • IVD in Cardiology and Neurology - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cardiovascular and Neurodegenerative Disorders Drives Demand for IVD Biomarkers
    • OEM Focus on Early Diagnosis and Risk Stratification Supports Adoption of Specialized IVD Panels
    • Growing Awareness of Stroke and Heart Attack Prevention Boosts Demand for Rapid Testing in Emergency Settings
    • Expansion of Point-of-Care Testing Capabilities Enhances IVD Use in Pre-Hospital and Critical Care Scenarios
    • Increased Investment in High-Sensitivity Troponin and NT-proBNP Assays Fuels Cardiac Test Innovation
    • OEM Innovation in Multi-Biomarker Panels Enables Comprehensive Cardiometabolic and Neuro Panel Testing
    • Integration of IVD With Imaging and EHR Systems Supports Clinical Decision-Making in Cardiology and Neurology
    • Rising Demand for Cost-Effective Stroke Risk Screening Tools Drives Expansion of Blood-Based Diagnostics
    • Expansion of Telecardiology and Teleneurology Services Fuels Need for Decentralized IVD Testing Platforms
    • Growth in Chronic Care Management Models Supports Regular Monitoring of Cardiac and Neurological Biomarkers
    • OEM Development of At-Home and Wearable IVD Devices Enhances Access to Long-Term Disease Monitoring
    • Aging Global Population and Increased Dementia Screening Drive Market for Alzheimers-Related Biomarkers
    • Rising Use of Genetic and Proteomic Testing in Neurology Drives Integration of IVD in Precision Medicine
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World IVD in Cardiology and Neurology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for IVD in Cardiology and Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Clinical Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • JAPAN
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • CHINA
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • EUROPE
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for IVD in Cardiology and Neurology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • FRANCE
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • GERMANY
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • INDIA
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for IVD in Cardiology and Neurology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for IVD in Cardiology and Neurology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • AFRICA
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030

IV. COMPETITION